Medpace (MEDP) Stock May Be 3% Stretched As $1b Buyback Starts

Medpace Holdings has delivered strong long term share gains, and the current price puts a spotlight on whether the underlying cash flows are enough to support that valuation. With investors reacting to fresh corporate actions and guidance, the key issue now is how the stock lines up against its own cash generation when run through a Discounted Cash Flow (DCF) lens.

• Over the past 5 years, Medpace Holdings has returned 214.6%, which raises the question of how much of that move is backed by the stream of cash the business can realistically produce.
• The newly approved US$1b share repurchase plan funded from cash on hand may support per share cash flow over time, since fewer shares can spread the same future cash generation across a smaller base.
• Prefer to judge Medpace Holdings on earnings? See why Medpace Holdings's 37.6x P/E tells a different valuation story.

The issue now is whether Medpace Holdings' current share price around US$662.48 is in line with the intrinsic value suggested by its projected cash flows under a Discounted Cash Flow (DCF) framework.

If you want to stress test the same cash flow question across a wider set of companies, take a look at 33 high quality undervalued stocks.

Does Medpace Holdings Look Fairly Valued on Cash Flow?

The Discounted Cash Flow (DCF) approach here focuses on what Medpace Holdings can return to shareholders through future free cash flow. The latest twelve-month free cash flow sits at about $706 million, and the model assumes that this cash generation continues to grow over time rather than shrink. Projected free cash flow by 2030 is higher than today on this view, with a gradual tempering of growth beyond that point as the business matures.

Those cash flows, when discounted back and compared with the current share price of $662.48, suggest Medpace Holdings is broadly in line with what this cash flow model implies. The newly announced $1b buyback program running through 2028 matters here because steady repurchases funded from existing cash can lift per share cash flow even if total dollars of free cash flow stay similar. That combination helps explain why the DCF projections put Medpace Holdings' estimated intrinsic value broadly in line with the current share price. Find out what Medpace Holdings could be worth using our Discounted Cash Flow (DCF) estimate.

The Medpace Holdings Narrative: What Would Justify Today's Price?

Narratives for Medpace Holdings pick up where the DCF discussion leaves off and explain which combinations of future growth, profitability and earnings power would need to hold for the stock to be worth meaningfully more or less than today’s price. All of these are housed on Simply Wall St’s Community page. Rather than focusing on a single valuation output, each narrative lays out its underlying assumptions so you can compare those expectations with actual results as they are reported.

Community views on Medpace Holdings are split between a modest undervaluation story and a richer price that already bakes in a lot of success.

Bull case: 5% undervalued

"Record net new business awards in Q2 2026, together with management’s decision to keep growing headcount at a high single digit rate..."

Discover why this Narrative puts Medpace Holdings at 5% undervalued.

Bear case: 24% overvalued

"Most customers can terminate a clinical-trial contract without cause on 30 days’ notice, Medpace is generally paid for work already completed..."

Explore why this Narrative puts Medpace Holdings at 24% overvalued.

Medpace Holdings: the share price is only one part of the story

Cash flows and community narratives tell a lot about Medpace Holdings, but recent activity from people inside the business adds another layer that deserves a closer look. See the recent insider selling flagged for Medpace Holdings.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com